Minerva Neurosciences logo

Pipeline Targeting a Range of Unmet Needs in CNS

Innovation & Pipeline

Minerva Neurosciences is focused on the central nervous system (CNS) disease pharmaceutical market. Our pipeline targets the treatment of schizophrenia, major depressive disorder (MDD), insomnia and mood disorders, and Parkinson’s disease, each of which affects millions of people around the world.

According to Datamonitor, an independent market research firm, in 2015 approximately 3.2 million people suffered from schizophrenia, 30 million suffered from MDD and 2.0 million suffered from Parkinson’s disease in the United States, Japan and the five major European Union markets of France, Germany, Italy, Spain and the United Kingdom. Insomnia is believed to affect approximately 30 to 35 percent of the global population as estimated by American Academy of Sleep Medicine.

Currently available treatment options for these conditions are known to have significant limitations that often result in high rates of discontinuation of therapy and unsatisfactory efficacy and safety profiles. Patients, physicians and family members also face significant challenges associated with the burden of these and many other CNS diseases.

We are pursuing the development of new therapeutic options based on our deep knowledge of the pathology of CNS diseases, the pharmacology of our compounds and our understanding of desired outcomes for unmet patient needs.

Minerva’s Pipeline

We currently have a portfolio of first-in-class product candidates in the pipeline: MIN-101, MIN-202, MIN-117 and MIN-301.

clinical

  •  
    PRE-CLINICAL
    PHASE I
    PHASE II
    MILESTONES
  • Positive top line results announced May 2016.

    Positive extension phase results announced October 2016.
  • Positive top line results announced January 2016 (Insomnia).
    Positive top line results announced March 2016 (MDD).
  • Positive top line results announced May 2016.
  • IND or IMPD; Phase I expected to initiate thereafter.

Pipeline of Next Generation Central Nervous System Pharmaceuticals (Status as of March 2017)

Your browser is out-of-date!

Update your browser to view this website correctly.Update my browser now

×